Get the Stockscreener App
5.47
5.82%
-0.37
Eupraxia Pharmaceuticals Inc stock is traded at $5.47, with a volume of 12,195.
It is down -5.82% in the last 24 hours and up +39.59% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$5.84
Open:
$5.75
24h Volume:
12,195
Relative Volume:
0.94
Market Cap:
$142.68M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-7.1039
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+27.61%
1M Performance:
+39.59%
6M Performance:
+75.72%
1Y Performance:
+118.25%
1-Day Range:
$5.3911
$5.75
1-Week Range:
$4.40
$6.1999
52-Week Range:
$2.20
$6.1999
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.3911 | 142.68M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.98 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.21 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.23 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.57 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Trading (EPRX.WT.A) With Integrated Risk Controls - news.stocktradersdaily.com
(EPRX) Strategic Investment Report (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Canaccord Genuity Group - Defense World
Canaccord Genuity initiates Eupraxia stock with spec. buy on EoE treatment - Investing.com Canada
(EPRX.WT.A) Dynamic Trading Report - news.stocktradersdaily.com
Millennium Management LLC Invests $31,000 in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) - Defense World
(EPRX) Technical Pivots with Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Shares Down 1.1% – Should You Sell? - Defense World
When the Price of (EPRX.WT.A) Talks, People Listen - news.stocktradersdaily.com
(EPRX) Strategic Equity Report (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Market Performance Analysis - news.stocktradersdaily.com
(EPRX) Investment Report (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX) (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Price Down 0.8% – Should You Sell? - Defense World
(EPRX) Advanced Equity Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals - TipRanks
Why Broadcom Stock Blew Past the Market on Monday - The Globe and Mail
Why Meta Platforms Stock Soared on AI News Today - The Globe and Mail
Hogs Close Mixed on Monday - The Globe and Mail
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders - GlobeNewswire
Stocks in play: Ares Strategic Mining Inc - The Globe and Mail
Should You Buy Paylocity Stock Despite its 7% Dip in 3 Months? - The Globe and Mail
Most Anticipated Earnings this Week – Week of June 2, 2025 - The Globe and Mail
E3 Lithium Provides Progress Update for the Demonstration Facility - The Globe and Mail
(EPRX.WT.A) Stock Market Analysis - news.stocktradersdaily.com
(EPRX) Investment Strategy and Analysis (EPRX:CA) - news.stocktradersdaily.com
(EPRX.WT.A) Equity Market Report - news.stocktradersdaily.com
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
(EPRX) Market Performance Analysis (EPRX:CA) - news.stocktradersdaily.com
Definity Financial Corporation Announces Increased Size of Previously Announced Private Placements of Common Shares to $385 million - The Globe and Mail
Should You Buy High-Yield Enterprise Products Partners While It's Below $36? - The Globe and Mail
(EPRX.WT.A) Technical Patterns and Signals - news.stocktradersdaily.com
Eupraxia Pharmaceuticals (OTCMKTS:EPRXF) Trading Down 0% – Here’s What Happened - Defense World
Travel + Leisure Up 10% in a Month: Hold Steady or Lock in Gains? - The Globe and Mail
(EPRX) Strategic Market Analysis (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc - Stockhouse
(EPRX) Long Term Investment Analysis (EPRX:CA) - news.stocktradersdaily.com
Long Term Trading Analysis for (EPRX.WT.A) - news.stocktradersdaily.com
“Bear-Pit Session” Highlights Peterson Capital’s Canada Growth Conference in Montreal - The Globe and Mail
11,613 Shares in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Acquired by Raymond James Financial Inc. - Defense World
(EPRX.WT.A) Comprehensive Trading Strategy Report - news.stocktradersdaily.com
Trading (EPRX) With Integrated Risk Controls (EPRX:CA) - news.stocktradersdaily.com
Raymond James Sticks to Its Buy Rating for Eupraxia Pharmaceuticals (EPRX) - The Globe and Mail
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - The Globe and Mail
Eupraxia Pharmaceuticals (EPRX) to Release Earnings on Wednesday - Defense World
(EPRX.WT.A) Trading Strategy and Analysis - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Host Virtual KOL Event to - GlobeNewswire
Nova Leap Health Corp. Posts Q1 2025 Results - The Globe and Mail
Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study - TipRanks
Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 - GlobeNewswire
Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results - Stock Titan
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.30%
0.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):